At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 206 enrolled
Drug / intervention
Bimekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis
In Brief
A Phase 2 clinical trial evaluating Placebo and Bimekizumab for Psoriatic Arthritis. Completed, enrolled 206 participants across 40 sites in 6 countries.
Detailed Summary
This is a study to evaluate the dose response based on the efficacy, safety and tolerability of bimekizumab in subjects with active psoriatic arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
CountriesCzechia, Germany, Hungary, Poland, Russia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartOct 2016
First PostedNov 2016
Primary CompletionNov 2017
Study CompletionJul 2018
TodayJul 2026
First PostedNov 21, 2016
Enrollment StartOct 1, 2016
Primary CompletionNov 1, 2017
Study CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.6 years ago
Interventions
Placeboother
Bimekizumabdrug
Bimekizumab in different dosage regimens.